[ ] | , ( ..) | , ( ..) | , ( ..) | , ( ..) | |
IRMA-2 [20] | 137/81 | 136/80 | 126/74 | 129/76 | |
RENAAL [21] | 166/90 | 166/90 | 145/80 | 148/82 | |
IDNT [22] | 144/84 | 144/84 | NA | NA | |
Kondo et al. [23] | 141/82 | 141/82 | NA | NA | |
SCOPE 24 | 117/74 | 117/73 | NA | NA | |
DIRECT-PREVENT-1 [17] | 129/76 | 128/76 | 127/75 | 126/76 | |
DIRECT-PROTECT-1 [17] | 139/82 | 140/83 | 133/78 | 136/80 | |
DIRECT-PROTECT-2 [18] | 142/78 | 141/77 | 132/72 | 137/74 | |
PROFESS [26] | 152/82 | 153/82 | 140/74 | 142/74 | |
TRANSCEND [27] | 131/77 | 131/78 | NA | NA | |
NAVIGATOR [28] | 160/87 | 158/87 | 140/77 | 144/80 | |
ORIENT [25] | 153/90 | 153/90 | 142/83 | 144/83 | |
ROADMAP [29] | 116/72 | 116/72 | NA | NA | |
Lewis et al. [33] | 137/85 | 140/86 | NA | NA | |
AIPRI [34] | 137/82 | 137/82 | 128/78 | 133/80 | |
HOPE [1] | 142/87 | 144/88 | NA | NA | |
PART-2 [5] | 146/82 | 145/82 | 143/80 | 143/80 | |
SCAT [6] | 136/83 | 136/83 | NA | NA | |
PROGRESS [3] | 123/74 | 123/74 | NA | NA | |
QUIET [7] | 128/77 | 132/78 | NA | NA | |
EUROPA [4] | 122/70 | 121/70 | 125/74 | 129/76 | |
PEACE [8] | 133/79 | 133/79 | 127/74 | 132/78 | |
CAMELOT [9] | 139/79 | 139/79 | 136/76 | 139/77 | |
DIABHYCAR [10] | 134/78 | 133/78 | 130/74 | 132/76 | |
DREAM [11] | 147/86 | 147/86 | 138/82 | 142/84 | |
IMAGINE [12] | 129/77 | 129/78 | 124/74 | 130/79 |
- ; - ; - . 1
3.
( ) | - | |||||
ARBs | IRMA-2 [20] | NA | NA | NA | NA | NA |
RENAAL [21] | NA | NA | NA | NA | ||
IDNT [22] | NA | |||||
Kondo et al. [23] | ||||||
SCOPE [24] | NA | NA | NA | NA | NA | |
DIRECT-PREVENT-1 [17] | NA | NA | ||||
DIRECT-PROTECT-1 [17] | ||||||
DIRECT-PROTECT-2 [18] | ||||||
PROFESS [26] | NA | NA | ||||
TRANSCEND [27] | NA | NA | NA | NA | NA | |
NAVIGATOR [28] | NA | NA | NA | |||
ORIENT [25] | NA | |||||
ROADMAP [29] | NA | NA | NA | NA | NA | |
ACE-Is | Lewis et al. [33] | NA | NA | NA | NA | NA |
AIPRI [34] | ||||||
HOPE [1] | NA | NA | ||||
PART-2 [5] | NA | NA | NA | |||
SCAT [6] | ||||||
PROGRESS [3] | NA | |||||
QUIET [7] | NA | NA | ||||
EUROPA [4] | NA | |||||
PEACE [8] | NA | |||||
CAMELOT [9] | ||||||
DIABHYCAR [10] | ||||||
DREAM [11] | NA | NA | NA | NA | NA | |
IMAGINE [12] |
. 1
|
|
, , () - 1000 - , , , . [35]:
= ( , 1000)
)
. -.
() metan (STATA 11.0, StataCorp, College Station, ). 95% () (intention-to-treat principle) [36, 37]. -, , , , , [38,39]. [40]. Q I2 . . - <0,05. () .
.
metareg [41 ] (STATA 11.0) - , , , , , , , [32]. , , - . , , , [42]. , , . tau-2 - ( ) (restricted maximum likelihood method), , [42]. , - (, , , , , ) , .
|
|
, .
, , . - Macaskill, I , [43].
, .
26 , -, . 1 3. 108 212 , 53 791 , 54 421 - . 2 6,5 [3,681,11). 5811 , 35% . 58,38,3 , 57,713,1 (=NS); 26% , , 44% (<0,05). (3,660,90 ) (3,691,32 ) (=NS). , , (27 25 1 000 -, =0,608), (21 19 1 000 -, =0,898), (7 6 1 000 -, =0,784) (15 24 1 000 , =0,176).
.
.
14,9% (: 0.830 [95% 0,744-0,927]; =0,001, =0,002) (. 2). , , - 10% (: 0,896 [95% 0,783-1,026], =0,112, =0,087), 17,7% (O: 0,811 [95% 0,748-0,879], <0,001, =0,438) 1 9,6% (O: 0,796 [95% 0,682-0,928], =0,004, =0,115). , 8,3% (O: 0,908 [95% 0,845-0,975], =0,008, =0,368) (. 2), 20,5% (O: 0,789 [95% 0,686-0,908], =0,001, =0,252), 13,7% (: 0,851 [95% 0,749-0,965], =0,01 2, =0,069). , , .
2.
() ; 95% () ; .
(A) ;
(B) .
;
|
|
3. 95%
* . . 2
.
7,0% (: 0,920 [95% 0,869-0,975], =0,005, =0,686) (. 2). , (: 1,033 [95% 0,847-1,260], =0,748, =0,01 2), 9,5% (: 0,903 [95% 0,803-1,01 5], =0,086, =0,420. 9,1 % (: 0.900 [95% 0,830-0,977], =0,011, =0,469). (: 1,006 [ 95% 0,941-1,075], =0,866, =0,368) (. 2) (: 0,892 [95% 0,7611,046], =0,159, =0,188). 10,6% (: 0,855 [95% 0,798-0,91 5], <0,001, =0,819). - . 3.
.
- . , , (: 0,915 [95% 0,853-0,982], =0,013), (: 0,768 [95% 0,679-0,869], <0,001) (: 0.580 [95% 0,370-0,908], =0,017) , (: 1,063 [95% 0,7481,509], =0,733), (: 0,728 [95% 0,357-1,482], =0,381), (: 0,949 [95% 0,597-1,508], =0,824) (: 0,861 [95% 0,661-1,122], =0.268) . . 4.
4